Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 8Ovarian Neoplasms 6Neoplasm Metastasis 4Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Fallopian Tube Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma, Ewing 1Primary Myelofibrosis 1Polycythemia Vera 1Neuroendocrine Tumors 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Mesothelioma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1

Interventions

Cyclophosphamide 37Rituximab 31fludarabine phosphate 26Filgrastim 20ibrutinib 19Bortezomib 19fludarabine 17Peripheral Blood Stem Cell Transplantation 15Lenalidomide 15Bendamustine Hydrochloride 14Etoposide 12Cytarabine 9aldesleukin 7Vorinostat 7Tacrolimus 7Radiotherapy 7Prednisone 7Paclitaxel 7Melphalan 7Cyclosporine 7Biopsy 7venetoclax 6tanespimycin 6sargramostim 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carmustine 6Vincristine 5Specimen Handling 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Mantle-Cell × talazoparib × Clear all
NCT01399840 2017-09-15

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Pfizer

Phase 1 Completed
33 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡